Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)

Intellia Therapeutics has reported Long-Term Investments over the past 7 years, most recently at $141.3 million for Q1 2026.

  • Quarterly Long-Term Investments rose 528.36% to $141.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $141.3 million through Mar 2026, up 528.36% year-over-year, with the annual reading at $155.2 million for FY2025, 250.74% up from the prior year.
  • Long-Term Investments was $141.3 million for Q1 2026 at Intellia Therapeutics, down from $155.2 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $225.0 million in Q1 2023 and troughed at $7.0 million in Q3 2025.
  • The 5-year median for Long-Term Investments is $46.8 million (2024), against an average of $76.2 million.
  • Year-over-year, Long-Term Investments tumbled 89.45% in 2022 and then soared 528.36% in 2026.
  • A 5-year view of Long-Term Investments shows it stood at $69.3 million in 2022, then skyrocketed by 44.02% to $99.9 million in 2023, then plummeted by 55.68% to $44.3 million in 2024, then soared by 250.74% to $155.2 million in 2025, then decreased by 9.01% to $141.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Long-Term Investments are $141.3 million (Q1 2026), $155.2 million (Q4 2025), and $7.0 million (Q3 2025).